Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness

被引：79

作者：

Ito, H ^{[1
]}

Gardner-Thorpe, J ^{[1
]}

Zinner, MJ ^{[1
]}

Ashley, SW ^{[1
]}

Whang, EE ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA

来源：

SURGERY | 2003年 / 134卷 / 02期

关键词：

D O I：

10.1067/msy.2003.224

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background. Src is a 60-kDa tyrosine kinase that plays a critical role in signal transduction associated with cell-extracellular matrix interactions. We tested the hypothesis that Src inhibition might suppress pancreatic cancer cellular invasiveness. Methods. We tested the effects of pyrazolopyrimidine (a Src kinase specific inhibitor) on 3 human pancreatic cancer cell lines: BXPC-3, MIAPaCa-2, and PANC-1. Src expression was assayed with Western blotting. Pyrazolopyrimidine-mediated inhibition of Src phosphorylation was confirmed by immunoprecipitation. Matrix metalloproteinase (MMP) activities and cellular invasive potential were assessed by use of zymography and Boyden chamber assays, respectively. Cell growth was assessed with the MTT assay. Results. Src was expressed in all 3 pancreatic cancer cell lines tested. Pyrazolopyrimidine completely suppressed Src phosphorylation, inhibited MMP2 (72kDa) and MMP9 (92kDa) activities by 40% to 34% (P < .05), and suppressed cellular invasiveness by more than 90% (P < .05) in all 3 cell lines. Pyrazolopyrimidine had variable effects on cell growth: 50 % reduction (P < .05) in BXPC-3, 7 % reduction (P > .05) in MIAPaCa-2, and 22 % reduction (P < .05) in PANC-1. Conclusion. Inhibition of Src signaling results in a marked reduction of pancreatic cancer cellular invasiveness. Src may represent a novel therapeutic target for this deadly cancer.

引用

页码：221 / 226

页数：6

共 24 条

[1] New functions for the matrix metalloproteinases in cancer progression [J].

Egeblad, M ;

Werb, Z .

NATURE REVIEWS CANCER, 2002, 2 (03) :161-174

[2] Role of matrix metalloproteinases and their inhibitors in pancreatic cancer [J].

Evans, JD ;

Ghaneh, P ;

Kawesha, A ;

Neoptolemos, JP .

DIGESTION, 1997, 58 (06) :520-528

[3] Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer [J].

Farrell, TJ ;

Barbot, DJ ;

Rosato, FE .

ANNALS OF SURGERY, 1997, 226 (01) :66-69

[4] Src in cancer: deregulation and consequences for cell behaviour [J].

Frame, MC .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (02) :114-130

[5]

Haier Jorg, 2002, J Exp Ther Oncol, V2, P237, DOI 10.1046/j.1359-4117.2002.01051.x

[6]

HERRON GS, 1986, J BIOL CHEM, V261, P2814

[7] ELECTROPHORETIC ANALYSIS OF PLASMINOGEN ACTIVATORS IN POLYACRYLAMIDE GELS CONTAINING SODIUM DODECYL-SULFATE AND COPOLYMERIZED SUBSTRATES [J].

HEUSSEN, C ;

DOWDLE, EB .

ANALYTICAL BIOCHEMISTRY, 1980, 102 (01) :196-202

[8] Role of Src expression and activation in human cancer [J].

Irby, RB ;

Yeatman, TJ .

ONCOGENE, 2000, 19 (49) :5636-5642

[9] Cancer statistics, 2003 [J].

Jemal, A ;

Murray, T ;

Samuels, A ;

Ghafoor, A ;

Ward, E ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26

[10]

Koshiba T, 1998, CANCER, V82, P642, DOI 10.1002/(SICI)1097-0142(19980215)82:4<642::AID-CNCR5>3.0.CO

← 1 2 3 →